FDA Approves Inluriyo (Imlunestrant) for ESR1-Mutated Breast Cancer
December 7, 2025 • ESR1 Mutated ER HER2 Advanced Breast Cancer Content Hub, Oncology, Oncology / Hematology, Women’s Health
On September 25, 2025, the FDA approved Inluriyo (imlunestrant) for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. This video explores the breakthrough, including clinical data from the EMBER-3 trial, as well as patient eligibility and dosing guidelines.
